Showing 2561-2570 of 3380 results for "".
- Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitishttps://practicaldermatology.com/news/realm-therapeutics-submits-investigational-new-drug-application-for-pr022-for-atopic-dermatitis/2458305/Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD). Pending acceptance, the IND will enable Realm to initiate a Phase 2a proof-of-concept trial for patients with atopic dermatitis.
- Beauty Drinks Poised to Be Cosmeceutical Industry's Next Billion-Dollar Babyhttps://practicaldermatology.com/news/beauty-drinks-poised-to-be-cosmeceutical-industrys-next-billion-dollar-baby/2458361/Beauty drinks are everywhere today, and many youth seekers turning to them as a way to improve skin and get their glow on from the inside out. In fact, beauty drinks are slated to become a billion dollar market, according to a new
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).
- US FDA Grants Orphan Drug Status to TXA127 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/us-fda-grants-orphan-drug-status-to-txa127-for-recessive-dystrophic-epidermolysis-bullosa/2458442/The U.S. Food and Drug Administration has granted Orphan Drug Status to TXA127 as a potential treatment for the rare genetic skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). TXA127 developer, Tarix Orphan LLC
- US FDA Issues Draft Updated Recommendations on Submitting a New 510(k) for Device Modificationshttps://practicaldermatology.com/news/us-fda-issues-draft-of-updated-recommendations-on-submitting-a-new-510k-for-device-modifications/2458471/The U.S. Food and Drug Administration (FDA) issued draft updated recommendations to help manufacturers determine when they are required to notify the FDA about modifications made
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- Is Eli Lilly's Taltz the Next Blockbuster Drug for Psoriasis?https://practicaldermatology.com/news/is-eli-lillys-taltz-the-next-blockbuster-drug-for-psoriasis/2458569/Eli Lilly’s new psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its efficacy and good safety profile, according to an analyst at GlobalData.
- FDA Approves New Combo Drug Plus Device Treatment for AKshttps://practicaldermatology.com/news/fda-approves-new-combo-drug-plus-device-treatment-for-aks/2458568/The FDA approved Biofrontera AG’s combination topical prescription drug Ameluz (BF-200 ALA) and medical device BF-RhodoLED for photodynamic therapy (PDT) treatment of mild-to-moderate actinic keratosis (AK) on the face and scalp. The approval covers lesion-directed as well as field-directed
- Phat Lips: Celebrity Lip Envy Driving Explosive Growth in Lip Enhancementhttps://practicaldermatology.com/news/phat-lips-celebrity-lip-envy-driving-explosive-growth-in-lip-enhancement/2458605/Someone gets their lips enhanced every 19 minutes in the US, the American Society of Plastic Surgeons (ASPS) reports. And a new ASPS survey suggests that celebrity lip envy may be driving this trend. The most likeable lips belong to Jennif